Evidence map›Paper›PMID 31427525›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

A unique variant of lymphocytic choriomeningitis virus that induces pheromone binding protein MUP: Critical role for CTL.

Brian C Ware, Brian M Sullivan, Stephanie LaVergne, Brett S Marro, Toru Egashira, Kevin P Campbell, John Elder, Michael B A Oldstone

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Brian C WareViral-Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Brian M SullivanViral-Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Stephanie LaVergneViral-Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Brett S MarroViral-Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Toru EgashiraDepartment of Molecular Physiology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242.
Kevin P CampbellDepartment of Molecular Physiology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242.
John ElderDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Michael B A OldstoneViral-Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037; mbaobo@scripps.edu.ORCID 0000-0003-0804-0501
Scripps Research Institute · USUniversity of Iowa · US

Funding

Therapeutic Potential of ESC-Derived Myogenic PrecursorsU54NS053672 · NINDS · UNIVERSITY OF IOWA · PI CAMPBELL, KEVIN P. · 2005 to 2019
$22.0M
RESEARCH IN INFECTIOUS DISEASEST32AI007036 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIZET, VICTOR · 1985 to 2025
$9.2M
PATHOGENESIS OF PERSISTENT VIRAL INFECTIONR01AI009484 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI OLDSTONE, MICHAEL B · 1985 to 2016
$7.2M
Host Genetic Factors to Combat Lassa Hemorrhagic FeverR01AI099699 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI OLDSTONE, MICHAEL B · 2013 to 2016
$1.9M
Genetic contributions to T cell mediated immunopathology after viral infectionR21AI145374 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SULLIVAN, BRIAN MARTIN · 2019 to 2020
$532k
Howard Hughes Medical InstituteNIAID NIH HHS R01 AI009484NIAID NIH HHS R01 AI099699NIAID NIH HHS R21 AI145374NIAID NIH HHS T32 AI007036NINDS NIH HHS U54 NS053672
6 · The paper itself

Abstract

Lymphocytic choriomeningitis virus (LCMV) WE variant 2.2 (v2.2) generated a high level of the major mouse urinary protein: MUP. Mice infected with LCMV WE v54, which differed from v2.2 by a single amino acid in the viral glycoprotein, failed to generate MUP above baseline levels found in uninfected controls. Variant 54 bound at 2.5 logs higher affinity to the LCMV receptor α-dystroglycan (α-DG) than v2.2 and entered α-DG-expressing but not α-DG-null cells. Variant 2.2 infected both α-DG-null or -expressing cells. Variant 54 infected more dendritic cells, generated a negligible CD8 T cell response, and caused a persistent infection, while v2.2 generated cytotoxic T lymphocytes (CTLs) and cleared virus within 10 days. By 20 days postinfection and through the 80-day observation period, significantly higher amounts of MUP were found in v2.2-infected mice. Production of MUP was dependent on virus-specific CTL as deletion of such cells aborted MUP production. Furthermore, MUP production was not elevated in v2.2 persistently infected mice unless virus was cleared following transfer of virus-specific CTL.

Indexed as

AnimalsCD8-Positive T-LymphocytesDystroglycansGene Expression RegulationLymphocytic ChoriomeningitisLymphocytic choriomeningitis virusMiceProteinsDag1 protein, mouseDystroglycansmajor urinary proteinsProteinscytotoxic T lymphocytes (CTL)lymphocytic choriomeningitis virus (LCMV)MUPpheromones

Identifiers

PMID31427525
PMCPMC6731760
OpenAlexW2969709724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.